Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide · DARUNAVIR 800 mg/1; COBICISTAT 150 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE 10 mg/1 · Tablet, Film Coated · Oral · Janssen Products LP
NDC 59676-0800-30 · 30 TABLET, FILM COATED in 1 BOTTLE · NDA · View full market →
Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $152.95 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
| Type | Number / code | Expires |
|---|---|---|
| patent | 10786518 | Jul 19, 2038 |
| patent | 10039718 | Oct 6, 2032 |
| patent | 8754065 | Aug 15, 2032 |
| patent | 9296769 | Aug 15, 2032 |
| patent | 8148374 | Sep 3, 2029 |
| patent | 7700645 | Dec 26, 2026 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Patheon Inc. | DARUNAVIR 800 mg/1; COBICISTAT 150 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE 10 mg/1 | Aug 20, 2026 | Sep 3, 2026 |
| Janssen Products LP | DARUNAVIR 800 mg/1; COBICISTAT 150 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE 10 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Janssen Products LP | DARUNAVIR 150 mg/1; COBICISTAT 800 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE 10 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Patheon Inc. | DARUNAVIR 150 mg/1; COBICISTAT 800 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE 10 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Janssen Products LP | COBICISTAT 150 mg/1; DARUNAVIR 800 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE 10 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Patheon Inc. | COBICISTAT 150 mg/1; DARUNAVIR 800 mg/1; EMTRICITABINE 200 mg/1; TENOFOVIR ALAFENAMIDE 10 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Symtuza — NDC 59676-0800-30," retrieved September 3, 2026, https://drugdashboards.com/drug/59676080030.
Free to cite with attribution — see how the data is put together.